

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/064738 A3

(51) International Patent Classification⁷: **C07D 211/06**,
A61K 31/4468, A61P 25/14, 25/16, 25/18, 25/28, 25/24,
25/06

San Diego, CA 92130 (US). BRANN, Mark, R. [US/US];
2950 Racetrack View Drive, Del Mar, CA 92014 (US).

(21) International Application Number:

PCT/US2004/001234

(74) Agent: HART, Daniel; Knobbe, Martens Olson & Bear,
LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/441,406 16 January 2003 (16.01.2003) US
60/479,346 17 June 2003 (17.06.2003) US

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (for all designated States except US): ACA-
DIA PHARMACEUTICALS INC. [US/US]; 3911 Sor-
rento Valley Blvd., San Diego, CA 92121-1402 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): WEINER, David,
M. [US/US]; 4915 Muir Avenue, San Diego, CA 92107
(US). DAVIS, Robert, E. [US/US]; 13272 Glencliff Way,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGEN-
ERATIVE DISEASES



(57) Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT_{2A/2C} receptor inverse agonist, demonstrate *in vivo* efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT_{2A/2C} receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

WO 2004/064738 A3



Published:

— with international search report

(88) Date of publication of the international search report:

25 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/001234

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D211/06 A61K31/4468 A61P25/14 A61P25/16 A61P25/18 A61P25/28 A61P25/24 A61P25/06		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07D A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 877 173 A (FARBER NURI B ET AL) 2 March 1999 (1999-03-02) claims 1,30	9-13
X	US 3 983 234 A (SAYERS ANTHONY CAMPBELL) 28 September 1976 (1976-09-28) column 1, line 1 - line 17	9-13, 17-20
X	FRIEDMAN J H: "Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 9, no. 3, 1 May 1994 (1994-05-01), pages 321-324, XP009032726 page 321, right-hand column, paragraph 3 page 323, right-hand column, paragraph 3 ----- -/--	25-28
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *G* document member of the same patent family		
Date of the actual completion of the international search 14 July 2004		Date of mailing of the international search report 08/09/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Albayrak, T

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US2004/001234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>YOSHIDA K ET AL: "Marked improvement of tardive dystonia after repoacing haloperidol with risperidone in a schizophrenic patient" CLINICAL NEUROPHARMACOLOGY, vol. 21, no. 1, 1998, pages 68-69, XP009032725 page 69, left-hand column - right-hand column</p> <p>-----</p>	25-28
X	<p>DELECLUSE F ET AL: "A case of tardive tremor successfully treated with clozapine" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 13, no. 5, September 1998 (1998-09), pages 846-847, XP009032724 the whole document</p> <p>-----</p>	25-28
X	<p>FACTOR S A ET AL: "Clozapine prevents recurrence of psychosis in Parkinson's disease" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 7, no. 2, 1992, pages 125-131, XP009032679 page 130, right-hand column, paragraph 2</p> <p>-----</p>	32-35,39
X	<p>FACTOR ET AL: "Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial" MOVEMENT DISORDERS OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, vol. 16, no. 1, January 2001 (2001-01), pages 135-139, XP009032680 page 138, right-hand column, paragraph 2</p> <p>-----</p>	32-35,39
X	<p>US 2002/165225 A1 (KANKAN RAJENDRA N ET AL) 7 November 2002 (2002-11-07) page 1, right-hand column, paragraph 8 - page 2, left-hand column, paragraph 1 claims 12,16</p> <p>-----</p>	32-35, 39-44,46
X	<p>US 6 358 698 B1 (BRANN MARK R ET AL) 19 March 2002 (2002-03-19) claims 9,10 column 1, paragraph 1 column 4, line 60 - line 64 column 5, line 59 - column 6, line 14 tables 2,3</p> <p>-----</p>	32-35, 39-44,46
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/001234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HERRICK-DAVIS ET AL: "Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine_{2C} Receptors" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 295, no. 1, October 2000 (2000-10), pages 226-295, XP001182089 figures 1-3 table 1</p> <p>-----</p>	1-86

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/001234

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5877173	A	02-03-1999	NONE	
US 3983234	A	28-09-1976	NONE	
US 2002165225	A1	07-11-2002	US 6348458 B1 AT 6739 U1 AU 2017601 A CA 2395774 A1 DE 20023184 U1 DK 200300161 U1 DK 200300221 U1 DK 200300222 U1 EP 1246827 A1 WO 0147933 A1 NZ 519926 A ZA 200205228 A IN 187439 A1	19-02-2002 25-03-2004 09-07-2001 05-07-2001 03-04-2003 16-06-2003 25-08-2003 25-08-2003 09-10-2002 05-07-2001 27-02-2004 30-06-2003 27-04-2002
US 6358698	B1	19-03-2002	AU 6391299 A WO 0020636 A1	26-04-2000 13-04-2000




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 413/12, 405/12, 417/12, 409/12, A61K 31/645	A1	(11) International Publication Number: WO 95/17400 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/CA94/00687 (22) International Filing Date: 14 December 1994 (14.12.94) (30) Priority Data: 08/172,208 23 December 1993 (23.12.93) US (71) Applicant: ALLELIX BIOPHARMACEUTICALS INC. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). (72) Inventors: TEHIM, Ashok; Suite 506, 115 Hillcrest Avenue, Mississauga, Ontario L5B 3Y9 (CA). FU, Jian-Min; 38 Sol- way Avenue, Brampton, Ontario L6Z 4E3 (CA). RAKHIT, Sumanas; Unit 20, 1020 Walden Circle, Mississauga, Ont- ario L5J 4J9 (CA). (74) Agents: HIRONS, Robert, G. et al.; Ridout & Maybee, Suite 2300, 101 Richmond Street West, Toronto, Ontario M5H 2J7 (CA).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>

(54) Title: N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RE-
CEPTOR LIGANDS

(57) Abstract

Described herein are D4 receptor-selective compounds of general formula (I) wherein A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings; X₁ is selected from CH₂, O, NH, S, C=O, CH-OH, CH-H(C₁₋₄alkyl)₂, C=CHCl, C=CHCN, N-C₁₋₄alkyl, N-acetyl, SO₂ and SO; X₂--- is selected from N=, CH₂-, CH=, C(O)-, O-, and S-; R₁ represents C₁₋₄alkyl; Y is selected from CH and N; n is 0, 1 or 2; q is 1 or 2; R₂ is C₁₋₆alkyl optionally incorporating a heteroatom selected from N, O and S; D is cyclohexane or benzene; and E is a saturated or unsaturated 5- or 6-membered heterocycle incorporating 1, 2 or 3 heteroatoms selected from O, N, and S, wherein E is optionally substituted with 1 or 2 substituents selected from halogen, C₁₋₄alkyl and halogen-substituted C₁₋₄alkyl; and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

N-HETEROBICYCLYL-PIPERAZINYL OR -PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS

This invention relates to compounds that bind to the dopamine D4 receptor, to their preparation and their use for therapeutic and drug screening purposes.

Background to the Invention

Neuronal cell receptors that bind the neurotransmitter dopamine constitute a group of at least five structurally distinct proteins that can now be produced using recombinant DNA techniques. These techniques have been applied to construct cell lines that incorporate the dopamine receptor in their membranes, to provide regenerable and homogeneous substrates with which chemical libraries can be screened to identify potential CNS-active drugs.

Recent evidence strongly implicates the dopamine receptor classified as D4 in the etiology of schizophrenia. It has been suggested that compounds capable of interfering with the function of this receptor, which is present in schizophrenics at levels that are six times normal, would be useful in the treatment of this disease (Seeman et al, Nature, 1993, 365:441). Some drugs currently on the market in fact exhibit the desired antagonism of D4 receptor activity, and bind with relative strong affinity to the receptor. Yet because of their structure, these drugs interact also with related dopamine receptors, particularly the D2 receptor type, which results in significant side effects that include altered motor function and tachycardia. It would be desirable to provide compounds that exhibit not only a high degree of affinity for the D4 receptor, but also a relatively low degree of affinity for the D2 receptor. In this specification, this desired combination of receptor binding properties is referred to as D4 selectivity.

Products currently marketed to treat indications in which the D4 receptor function is implicated include the dibenzodiazepine, clozapine, and the dibenzoxazepine, isloxapine. Analysis of their dopamine receptor binding

properties has shown that the preference for binding the D4 receptor relative to the D2 receptor is about 10 fold, for both products. Similarly, both bind the D4 receptor with about the same affinity (K_i value approximately 20 nM). Other products, recently published in the scientific literature, have shown similar D4 to D2 selectivity profile and D4 affinity values.

It is an object of the present invention to provide a compound having an improved D4 selectivity profile.


It is another object of the present invention to provide a compound having an improved D4 binding affinity.

It is another object of the present invention to provide a compound having both an improved D4 selectivity profile and D4 binding affinity.

It is a further object of the present invention to provide a pharmaceutical composition comprising a compound of the present invention, as active ingredient.

Summary of the Invention

According to one aspect of the present invention, there is provide a compound of Formula I:



wherein:

A and B are independently selected, optionally substituted, saturated or

unsaturated 5- or 6-membered, homo- or heterocyclic rings;
 X_1 is selected from CH_2 , O, NH, S, C=O, CH-OH, CH-N(C_{1-4} alkyl) $_2$,
C=CHCl, C=CHCN, N- C_{1-4} alkyl, N-acetyl, SO_2 and SO;
 X_{2---} is selected from N=, CH_2- , CH=, C(O)-, O-, and S-;
Y is selected from CH and N;
 R_1 represents C_{1-4} alkyl;
n is 0, 1 or 2;
q is 1 or 2;
 R_2 is C_{1-6} alkyl optionally incorporating a heteroatom selected from N, O and S;
D is cyclohexane or benzene; and
E is a saturated or unsaturated 5- or 6-membered heterocycle incorporating
1, 2 or 3 heteroatoms selected from O, N, and S, wherein E is
optionally substituted with 1 or 2 substituents selected from halogen,
 C_{1-4} alkyl and halogen-substituted C_{1-4} alkyl;
and acid addition salts, solvates and hydrates thereof.

According to another aspect of the invention, there is provided a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.


In a further aspect of the invention, there is provided an analytical method in which a compound of the invention is used either to distinguish the D4 receptor from other receptor types or from the D2 receptor.

These and other aspects of the present invention are now described in greater detail hereinbelow.


Detailed Description and Preferred Embodiments

The invention relates to compounds that bind the dopamine D4 receptor in a selective manner, relative to the dopamine D2 receptor. It has been found, more particularly, that the D4 selectivity of D4-binding ligands having


the tricyclic structure:



is significantly improved when the piperazine group is derivatized by a function having the structure:



In accordance with one of its aspects, the present invention accordingly provides compounds that conform to Formula I:



In embodiments of the invention, the rings D and E together form an optionally bicyclic structure, in which ring D is benzene and ring E is a 5- or 6-membered heterocycle that comprises 2 or 3 heteroatoms selected from O, N and S. Ring E is optionally substituted with 1 or 2 substituents selected from halogen such as Cl or F; C₁₋₄alkyl such as methyl; and halogen-substituted C₁₋₄alkyl such as trifluoromethyl. Particular embodiments of the invention include those in which ring D is benzene and ring E is a saturated,

5-membered ring containing two heteroatoms, such as 1,3-dioxolane, thiazole, imidazole, 2-imidazoline, imidazolidine, and 1,2,3-triazole. In a specific embodiment of the invention, rings D and E together form 1,3-benzodioxolane.

The R_2 function coupled between ring D and the piperaziny group is, in embodiments of the invention, a linear or branched chain C_{1-8} alkylene group such as $-CH_2-$,

$-CH(CH_3)-$, $-C(CH_3)_2-$ and $-CH_2-CH_2-$. The C_{1-8} alkylene group may be interrupted or terminated by a heteroatom such as oxygen or sulfur, to form a group such as

$-O-CH_2-$, $-CH_2-O-CH_2-$, $-CH_2-O-$. The R_2 group can be coupled to ring D at the meta/para position.

In a specifically preferred embodiment of the invention, the function represented in Formula I by the symbols $-R_2-D/E$ is the piperonyl group.

The tricyclic function to which the R_2-D/E function is coupled can have various structures and will typically incorporate those found to be important for dopamine D4 receptor binding. In other words, the tricycles suitable for coupling to the R_2-D/E function are those which, when substituted by functions other than R_2-D/E , are determined by the assay herein described to bind the D4 receptor (preferably the human D4 receptor) with an affinity not greater than $1\mu M$ (K_i). In particular, the rings A and B are selected, according to embodiments of the invention, from benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, triazole, pyrazole, thiophene, thiazole, and pyran. In a particular embodiment, ring A is selected from benzene and pyridine and ring B is selected from benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, triazole, pyrazole, thiophene, thiazole, furan and pyran; and is particularly selected from benzene and pyridine. In specific embodiments of the invention, both ring A and B are benzene. It is to be appreciated that when rings A and B are heterocycles, the heteroatoms are shared with the central seven

membered ring only when the shared heteroatom is N. Such tricycles are within the scope of the Formula I; one embodiment of which is described by Lednicer et al in The Organic Chemistry of Drug Synthesis, (1992, John Wiley & Sons Inc., New York) wherein ring B is imidazole that is fused to a thiazepine at one of the imidazole nitrogen atoms.

One or both rings A and B may be substituted with from 1 to 3, usually 1 or 2, substituents. When substituted, the substituents are selected from hydroxyl, halo, C₁₋₄alkyl, amino, nitro, cyano, halo-substituted C₁₋₄alkyl, C₁₋₄alkoxy, halo-substituted C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄acyl, halo-substituted C₁₋₄acyl, cyclo-C₃₋₇alkyl, thio-C₁₋₄alkylene, C₁₋₄alkylthio, halo-substituted C₁₋₄alkylthio, cyanothio, tetrazolyl, N-piperidinyl, N-piperazinyl, N-morpholinyl, acetamido, C₁₋₄alkylsulfonyl, halosulfonyl, halo-substituted C₁₋₄alkylsulfonyl, C₁₋₄alkylsulfoxyl, sulfonamido, C₁₋₄alkylseleno, and OSO₃H.

Substitution sites on rings A and B will be limited in practice to the carbon atoms on the ring that are not shared with the central seven membered ring. For example, a benzene ring can accommodate up to 4 substituents; pyridine, and pyran rings can accommodate up to 3 substituents; pyrimidine, pyrazine, pyridazine, pyrrole, furan and thiophene rings can accommodate up to 2 substituents; imidazole, pyrazole and thiazole rings can accommodate only 1 substituent; and a triazole ring can accommodate no substituents. It is also to be understood that rings A and B may incorporate substituents at nitrogen atoms on the ring that are not shared with the central seven membered ring. For example the NH member of an imidazole ring may be substituted. In particular embodiments, rings A and B are substituted with from 1 to 2 substituents selected from chloro, fluoro, methyl, trifluoromethyl, methoxy, nitro, cyano and methylthio. In particularly preferred embodiments ring A is benzene substituted with 1 or 2 substituents selected from chloro, methyl, nitro and cyano and ring B is benzene substituted with 1 or 2 substituents selected from chloro, methoxy, trifluoromethyl and nitro.

In the central, 7-membered ring of the tricycle, X_1 may be any one of CH_2 , O, NH, S, C=O, CH-OH, CH-N(C₁₋₄alkyl)₂, C=CHCl, C=CHCN, N-C₁₋₄alkyl, N-acetyl, SO₂ and SO, while X_{2---} may be any one of N=, CH₂-, CH=, C(O)-, O-, and S-. In a particular embodiment of the invention, X_1 is O, S or NH. In another embodiment, X_{2---} is N= or CH=. In a particularly preferred embodiment, X_1 is O, S or NH and X_{2---} is N= or CH=. In specific embodiments X_1 and X_{2---} are selected to form a seven membered ring selected from oxazepine, diazepine, thiazepine and thiepine.

In preferred embodiments X_1 and X_{2---} together with rings A and B are selected to form a tricycle that is selected from 5*H*-dibenzo[b,e][1,4]diazepine that is optionally substituted, for example with one of 7,8-dichloro, 7,8-dimethyl, 2-chloro, 3-chloro, 4-chloro, 2,4-dichloro, 4,7,8-trichloro, 2-trifluoromethyl, 1-fluoro, or 2-methoxy; dibenz[b,f][1,4]oxazepine that is optionally substituted, for example with one of 4-nitro, 8-chloro, 4-cyano or 4-chloro; dibenzo[b,f]thiepine that is optionally substituted, for example with one of 2-nitro or 2-chloro; 11*H*-dibenzo[b,f]thiepine that is optionally substituted, for example with 2-methylthio; and dibenzo[b,f][1,4]thiazepine that is optionally substituted, for example with 8-chloro. In a specific embodiment of the invention, X_1 and X_{2---} together with rings A and B are selected to form a tricycle that is selected from:

- dibenz[b,f][1,4]oxazepine;
- 8-chlorodibenz[b,f][1,4]oxazepine;
- 8-methyldibenz[b,f][1,4]oxazepine;
- 7,8-dimethyl-5*H*-dibenzo[b,e][1,4]diazepine;
- 5*H*-dibenzo[b,e][1,4]diazepine;
- 2-chloro-5*H*-dibenzo[b,e][1,4]diazepine;
- 8-chlorodibenzo[b,f][1,4]thiazepine;
- 4-chloro-5*H*-dibenzo[b,e][1,4]diazepine;
- 7,8-dichloro-5*H*-dibenzo[b,e][1,4]diazepine;
- 2-trifluoromethyl-5*H*-dibenzo[b,e][1,4]diazepine;
- 2,7,8-trichloro-5*H*-dibenzo[b,e][1,4]diazepine;

3-chloro-5*H*-dibenzo[b,e][1,4]diazepine;
2-methoxy-5*H*-dibenzo[b,e][1,4]diazepine;
4-cyanodibenz[b,f][1,4]oxazepine;
4-chlorodibenz[b,f][1,4]oxazepine;
4-nitrodibenz[b,f][1,4]oxazepine; and
2-nitrodibenzo[b,f]thiepine.

In a particular embodiment, X₁ and X₂--- together with rings A and B are selected to form a tricycle that is selected from:

dibenz[b,f][1,4]oxazepine;
8-chlorodibenz[b,f][1,4]oxazepine;
8-methyldibenz[b,f][1,4]oxazepine;
7,8-dimethyl-5*H*-dibenzo[b,e][1,4]diazepine;
5*H*-dibenzo[b,e][1,4]diazepine;
8-chlorodibenzo[b,f][1,4]thiazepine;
2-methoxy-5*H*-dibenzo[b,e][1,4]diazepine;
7,8-dichloro-5*H*-dibenzo[b,e][1,4]diazepine;
2-trifluoromethyl-5*H*-dibenzo[b,e][1,4]diazepine;
2,7,8-trichloro-5*H*-dibenzo[b,e][1,4]diazepine; and
2-nitrodibenzo[b,f]thiepine.

In a preferred embodiment, X₁ and X₂--- together with rings A and B are selected to form a tricycle that is selected from:

dibenz[b,f][1,4]oxazepine;
8-chlorodibenz[b,f][1,4]oxazepine;
8-methyldibenz[b,f][1,4]oxazepine;
7,8-dimethyl-5*H*-dibenzo[b,e][1,4]diazepine;
5*H*-dibenzo[b,e][1,4]diazepine;
8-chlorodibenzo[b,f][1,4]thiazepine; and
2-methoxy-5*H*-dibenzo[b,e][1,4]diazepine.

In another preferred embodiment, X₁ and X₂--- together with rings A and B are selected to form a tricycle that is selected from:

dibenz[b,f][1,4]oxazepine;
8-chlorodibenz[b,f][1,4]oxazepine;
7,8-dimethyl-5*H*-dibenzo[b,e][1,4]diazepine;
8-chlorodibenzo[b,f][1,4]thiazepine;
4-chloro-5*H*-dibenzo[b,e][1,4]diazepine;
7,8-dichloro-5*H*-dibenzo[b,e][1,4]diazepine;
2,7,8-trichloro-5*H*-dibenzo[b,e][1,4]diazepine;
3-chloro-5*H*-dibenzo[b,e][1,4]diazepine;
4-nitrodibenz[b,f][1,4]oxazepine;
2-nitrodibenzo[b,f]thiepine; and
2-chlorodibenzo[b,f]thiepine.

In another preferred embodiment, X₁ and X₂--- together with rings A and B are selected to form a tricycle that is selected from:

8-chloro-11-(4-piperonyl)-1-piperazinyldibenz[b,f][1,4]oxazepine;
2-methoxy-11-(4-piperonyl-1-piperazinyldibenzo[b,e][1,4]diazepine; and
2-nitro-10-(4-piperonyl-1-piperazinyldibenzo[b,f]thiepine.

In a more preferred embodiment, X₁ and X₂--- together with rings A and B are selected to form a tricycle that is selected from:

2-nitrodibenzo[b,f]thiepine; and
8-chlorodibenz[b,f][1,4]oxazepine.

In a most preferred embodiment, X₁ and X₂--- together with rings A and B form a tricycle that is 8-chlorodibenz[b,f][1,4] oxazepine.

In an embodiment of the invention, the ring coupled to the tricyclic structure may incorporate 0, 1 or 2 R₁ substituents that are C₁₋₄alkyl groups, such as methyl. The piperazinyll ring may incorporate an additional CH₂ group (q = 2) to form a diazepine ring as described by Horrom et al (US 4,096,261). In another embodiment of the invention, Y is N or CH thereby forming a piperazinyll or piperidinyll ring respectively. In particular embodiments of the

invention, n is 0; q is 1 and Y is N. In a specific embodiment n, q and Y are chosen to give an unsubstituted piperaziny ring.

Specific compounds of formula (I) include:

11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 8-chloro-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 8-methyl-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 7,8-dimethyl-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 2-chloro-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 8-chloro-11-(4-piperonyl)-1-piperaziny)-dibenzo[b,f][1,4]thiazepine;
 4-chloro-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 7,8-dichloro-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 2-trifluoromethyl-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 2,7,8-trichloro-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 3-chloro-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 2-methoxy-11-(4-piperonyl)-1-piperaziny)-5H-dibenzo[b,e][1,4]diazepine;
 4-cyano-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 4-chloro-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 4-nitro-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine; and
 2-nitro-10-(4-piperonyl)-1-piperaziny)-dibenzo[b,f]thiepine.

In a particular embodiment, there are provided compounds of formula (I) exhibiting better D₄selectivity than the corresponding 4-methyl piperazine compound, including:

11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 8-chloro-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;
 8-methyl-11-(4-piperonyl)-1-piperaziny)-dibenz[b,f][1,4]oxazepine;

7,8-dimethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
8-chloro-11-(4-piperonyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine;
2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
7,8-dichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
2-trifluoromethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
2,7,8-trichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; and
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.

In a more preferred embodiment, there are provided compounds of formula (I) exhibiting better D4 affinity and selectivity than the corresponding 4-methyl piperazine compound, including:

11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-methyl-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
7,8-dimethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
8-chloro-11-(4-piperonyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine; and
2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.

In a more preferred embodiment, there are provided compounds of formula (I) exhibiting better D4 selectivity than clozapine, including:

11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
7,8-dimethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;

8-chloro-11-(4-piperonyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine;
4-chloro-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine;
7,8-dichloro-11-(4-piperonyl-1-piperazinyl)-5*H*-
dibenzo[b,e][1,4]diazepine;
2,7,8-trichloro-11-(4-piperonyl-1-piperazinyl)-5*H*-
dibenzo[b,e][1,4]diazepine;
3-chloro-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine;
4-nitro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
4-cyano-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;
4-chloro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine; and
2-chloro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.

In a more preferred embodiment, there are provided compounds of formula
(I) exhibiting better D4 affinity than clozapine, including:

8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
2-methoxy-11-(4-piperonyl-1-piperazinyl)-5*H*-
dibenzo[b,e][1,4]diazepine; and
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.

In a more preferred embodiment, there are provided compounds of formula
(I) exhibiting better D4 affinity and selectivity than clozapine, including:

2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine; and
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine.

In a most preferred embodiment, there are provided compounds of formula
(I) that exhibit D4 affinity and selectivity that is better than clozapine and
the corresponding 4-methyl compound, such a compound is 8-chloro-11-(4-
piperonyl)-1-piperazinyl)-dibenz[b,f][1,4] oxazepine.


Acid addition salts of the compound of Formula I include for example those
formed with inorganic acids e.g. hydrochloric, sulphuric or phosphoric acids
and organic acids e.g. succinic, maleic, acetic or fumaric acid. Other non-

pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of compounds of Formula I for ligand use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt. Also included within the scope of the invention are solvates and hydrates of the invention.


The conversion of a given compound salt to a desired compound salt is achieved by applying standard techniques, in which an aqueous solution of the given salt is treated with a solution of base e.g. sodium carbonate or potassium hydroxide, to liberate the free base which is then extracted into an appropriate solvent, such as ether. The free base is then separated from the aqueous portion, dried, and treated with the requisite acid to give the desired salt.

It will be appreciated that certain compounds of Formula I may contain an asymmetric centre. Such compounds will exist as two (or more) optical isomers (enantiomers). Both the pure enantiomers and the racemic mixtures (50% of each enantiomer), as well as unequal mixtures of the two, are included within the scope of the present invention. Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention.

The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides, in a further aspect, a process for the preparation of a compound of Formula I or a salt, solvate or hydrate thereof, which comprises the step of coupling a reagent of Formula A:




with a reagent of Formula B:



using a Lewis acid such as TiCl_4 or $\text{BF}_3 \cdot \text{Et}_2\text{O}$.


Reagent (A) can be obtained commercially or can be synthesized using established ring closure procedures. For example, when X_1 is NH and X_2--- is N= (a diazepine), reagent (A) may be prepared according to the procedures described by Giani et al (Synthesis, 1985, 550) by refluxing equimolar amounts of 2-chlorobenzoic acid, *o*-phenylene-diamine and powdered copper in chlorobenzene. The following is a schematic representation of the reaction to obtain the diazepine form of reagent (A):



When X_1 is O and X_2--- is N= (an oxazepine), reagent (A) may be prepared according to the procedures described by Klunder (J. Med. Chem. 1992, 35:1887) by condensation of a 2-aminophenol with 2-chloro-5-nitrobenzoyl chloride in THF to afford the corresponding carboxamide followed by refluxing with NaOH for ring closure. The following is a schematic representation of the steps to obtain the oxazepine form of reagent (A):

The thiepine form of reagent (A), i.e. when X_1 is S and X_2--- is CH=, may be prepared according to the procedures described by Sindelar et al (Collect.


Czech. Chem. Commun, 1983, 48(4):1187). When reagent (A) is an oxepine i.e. when X_1 is O and X_{2---} is CH_2- , it may be prepared in the manner reported by Harris et al (J. Med. Chem., 1982, 25(7):855); and the corresponding cycloheptene reagent (A) i.e. when X_1 and X_{2---} are both CH_2 , may be prepared as reported by De Paulis et al (J. Med. Chem. 1981, 24(9):1021). The thiazepine reagent (A) may be prepared in a four step process starting from 1-bromo-2-nitrobenzene and methyl thiosalicylate. The steps involve coupling; reduction of the nitro group; hydrolysis of the ester group; and finally ring closure.



Many of the reagents of Formula B are similarly available from various commercial sources. In the alternative, or where the desired reagent B is not commercially available, it can be synthesized from the corresponding 1-piperazinecarboxyaldehyde by reaction with Halo- R_2 -D/E, where halo is desirably the bromo derivative. Regnier et al (US 3,119,826) describes the synthesis of piperonyl substituted piperazine by reacting piperazine with piperonyl chloride which is first prepared by chlorinating the corresponding alcohol with $SOCl_2$. The alcohol may be prepared by reducing the corresponding carboxy-substituted compound with a suitable reducing agent such as borane-THF complex or borane- Me_2S complex. The carboxyl compound may incorporate various heteroatoms in ring E which are

commercially available, for example benzothiazole-6-carboxylic acid (Maybridge 04-7305), 5-benzimidazolecarboxylic acid (Aldrich 29,678-3) and benzotriazole-5-carboxylic acid (Aldrich 30,423-9).

In the specific case where $Y = CH$, synthesis proceeds by coupling isonicotinic acid (4-piperonyl derivative thereof) with an amino reagent of the formula:



using a suitable coupling agent such as EDCI, to form an amide intermediate. The amino reagent may be obtained commercially or may be synthesized according to established synthetic techniques. For example, 2-chloronitrobenzene can be converted to the amino reagent 2-aminodiphenylsulphide (or oxide) by substitution with thiobenzene (or hydroxybenzene) in the presence of K_2CO_3 and then reducing in the presence of Zn. The resulting amide intermediate can then be cyclized with a suitable ring closure agent such as $POCl_3$ to give the final compound according to formula I wherein Y is CH.

For use as a ligand, the present compounds can be stored in packaged form for reconstitution and use. The compounds can be used to distinguish dopamine receptors from other receptor types, for example glutamate and opioid receptors, within a population of receptors and in particular to distinguish between the D4 and D2 receptors. The latter can be achieved by incubating preparations of the D4 receptor and of the D2 receptor with a D4 selective compound of the invention and then incubating the resulting preparation with a radiolabelled dopamine receptor ligand, such as 3H -spiperone. The D2 and D4 receptors are then distinguished by determining the difference in membrane-bound radioactivity, with the D4

receptor exhibiting lesser radioactivity, i.e., lesser ^3H -spiperone binding.

In another embodiment of the invention, the compound is provided in labelled form, such as radiolabelled form e.g. labelled by incorporation within its structure of ^3H or ^{14}C or by conjugation to ^{125}I . Such radiolabelled forms can be used to directly to distinguish between dopamine D4 and dopamine D2 receptors. Furthermore, radiolabelled forms of the present compounds can be exploited to screen for more potent dopamine D4 ligands, by determining the ability of the test ligand to displace the radiolabelled compound of the present invention.

The clozapine-like binding profile of the present compounds indicates their utility as pharmaceuticals that may be useful for the treatment of various conditions in which the use of a dopamine D4 receptor ligand is indicated, such as for the treatment of anxiety and schizophrenia.

For use in medicine, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides, in a further aspect, pharmaceutical compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof and a pharmaceutically acceptable carrier.

The compounds of the present invention may be administered by an convenient route, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions formulated accordingly.

The compounds and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the

compound or pharmaceutically acceptable salt in a suitable pharmaceutical liquid carrier for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier, for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilized and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively, the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering

valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as fluoro-chloro-hydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer.

Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, wherein the active ingredient is formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine.

Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

Preferably, the composition is in unit dose form such as a tablet, capsule or ampoule. Suitable unit doses i.e. therapeutically effective amounts; can be determined during clinical trials designed appropriately for each of the condition for which administration of a chosen compound is indicated and will of course vary depending on the desired clinical endpoint. It is anticipated that dosage sizes appropriate for administering the compounds of the examples will be roughly equivalent to, or slightly less than, those used currently for clozapine. Accordingly, each dosage unit for oral administration may contain from 1 to about 500 mgs, and will be administered in a frequency appropriate for initial and maintenance treatments.

Example 1

11-(4-piperonyl)-1-piperaziny]-dibenz[b,f][1,4]oxazepine

To a stirred solution of dibenz[b,f][1,4]oxazepin-11(10H)-one (0.500 g, 2.37 mmol; Aldrich) in dry toluene (20.0 mL) at room temperature was added 1-piperonylpiperazine (2.40 g, 10.89 mmol; Aldrich) followed by the dropwise addition of TiCl_4 (1M in toluene, 2.85 mL, 2.85 mmol). The

reaction mixture was refluxed for 2 hours, cooled to room temperature and then poured into an ammonium hydroxide solution (30%, 50 mL). The resulting mixture was extracted with dichloromethane (4x75 mL), and the combined organic phases were then dried (K_2CO_3) and concentrated. Purification of the product was conducted on silica gel using ethyl acetate:hexane (50:50) as the eluant to give 0.971 g (99%) of the title compound as a pale yellow solid; m.p. 128-130°C.

The hydrochloride salt of the title compound was subsequently prepared by dissolving the base (0.100 g, 0.242 mmol) in 1 mL of 3N-HCl in ethyl acetate, then stirring at room temperature for 15 minutes. The solution was removed under vacuum and the resulting oil was triturated with dry methanol (5.00 mL). The solvent was evaporated under reduced pressure to yield 0.111 g (quantitative) of the hydrochloride salt, as a colourless solid; m.p. 188-190°C (decomp.).

In a like manner, there is prepared the following additional compound:
11-(4-piperonyl)-1-piperaziny]-dibenzo[b,f][1,4]thiazepine,
from 10,11-dihydrodibenzo[b,f][1,4]thiazepin-11-one.

Example 2

8-chloro-11-(4-piperonyl)-1-piperaziny]dibenz[b,f][1,4]oxazepine

The title compound was produced in the manner described in example 1, but using the 8-chloro analog of dibenz[b,f][1,4]oxazepin-11(10*H*)-one as starting material, for reaction with 1-piperonylpiperazine. The 8-chloro compound was produced according to the protocol reported by Coyne and Cusic in J. Med. Chem., 1967, 10:541. Briefly, this entailed coupling potassium salicylaldehyde with 2,5-dichloronitrobenzene, followed by oxidation to the carboxylic acid, reduction of nitro, and finally ring closure, to yield the desired 8-chloro starting material (m.p. = 256 - 258°C).

The 8-chloro starting material was then reacted with 1-piperonylpiperazine

in the manner described in example 1, and the title compound was obtained as a colourless solid; m.p. = 62-64°C.

The hydrochloride salt of the title compound was subsequently prepared by dissolving the base (0.030 g, 0.067 mmol) in 0.3 mL of 3N-HCl in ethyl acetate, then stirring at room temperature for 15 minutes. The solution was removed under vacuum and the resulting oil was triturated with dry methanol (2.00 mL). The solvent was evaporated under reduced pressure to yield 0.033 g (quantitative) of the hydrochloride salt, as a colourless solid; m.p. = 176-178°C.

In a like manner, there is prepared the following additional compound:

8-chloro-11-(4-piperonyl)-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]

diazepine; from

8-chloro-10,11-dihydro-5*H*-dibenzo[b,e][1,4]diazepin-11-one; and

Example 3

8-methyl-11-(4-piperonyl)-1-piperazinyl)dibenz[b,f][1,4]oxazepine

The title compound was produced in the manner described in example 1, but using the 8-methyl analog of dibenz[b,f][1,4]oxazepin-11(10*H*)-one as starting material, for reaction with 1-piperonylpiperazine. The 8-methyl compound was produced according to the protocol reported by Klunder *et al.* in J. Med. Chem., 1992, 35:1887. Briefly, this entailed coupling 2-bromobenzoic acid with 2-amino-4-methylphenol, followed by cyclization using potassium hydroxide in dimethylformamide to yield the desired 8-methyl starting material (m.p. 207-208°C).

The 8-methyl starting material was then reacted with 1-piperonylpiperazine in the manner described in example 1, and the title compound was obtained (after recrystallization from 10% methylene chloride in hexanes) as white crystals; 50% yield; R_f (30% acetone/hexane) 0.4; m.p. 146-147°C; HRMS (FAB): MH⁺ for C₂₆H₂₆N₃O₃ calculated 428.1974, found 428.1939.

Example 4

7,8-dimethyl-11-(4-piperonyl)-1-piperazinyl-5H-dibenzo[b,f][1,4] diazepine

The title compound was produced in the manner described in example 1, but using the 7,8-dimethyl analog of 10,11-dihydro-5H-dibenzo[b,f][1,4]diazepin-11-one as starting material, for reaction with 1-piperonylpiperazine. The 7,8-dimethyl compound was prepared according to the procedure described by Giani *et al.* Synthesis, 1985, 550.

The 7,8-dimethyl starting material was then reacted with 1-piperonylpiperazine in the manner described in example 1, and the title compound was obtained as a yellow solid; 42% yield; R_f (50% acetone/hexane) 0.6; m.p. 176-178°C; HRMS (FAB): MH⁺ for C₂₇H₂₉N₄O₂ calculated 441.2291 found 441.2302.

Example 5

11-(4-piperonyl)-1-piperazinyl-5H-dibenzo[b,e][1,4]diazepine

The desired starting material 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one was produced according to the protocol reported by Giani et.al. (*supra*). The tricyclic lactam was then reacted with 1-piperonylpiperazine in the manner described in example 1, and the title compound was obtained as a yellow solid (50%) ; m.p. 136-38°C.

Example 6

2-Chloro-11-(4-piperonyl)-1-piperazinyl-5H-dibenzo[b,e][1,4] diazepine

The desired starting material 2-chloro-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one was produced according to the protocol reported by Giani et.al. (*supra*). The 2-chloro lactam was then reacted with 1-piperonylpiperazine in the manner described in example 1, and the title compound was obtained as a yellow-orange solid (92%); m.p. 60-64°C.

Example 7

8-chloro-11-(4-piperonyl)-1-piperazinyldibenzo[b,f][1,4] thiazepine

The desired starting material 8-chloro-10,11-dihydrodibenzo[b,f][1,4]thiazepine-11-one was prepared in four steps starting from 2,5-dichloronitrobenzene and methyl thiosalicylate. The steps involved were coupling; reduction of nitro group; hydrolysis of ester group; and ring closure.

A solution of NaH (1.1 g, 40 mmol) in dry THF (20 mL) was cooled to 0°C. To this mixture methyl thiosalicylate (5.1 mL, 36 mmol) was added dropwise via syringe. The reaction mixture was warmed to room temperature to ensure completion of the reaction. The solution was cooled to 0°C and 2,5-dichloronitrobenzene (7.0 g, 36 mmol) was added dropwise in THF (20 mL). The reaction was stirred at 0°C for 30 minutes then stirred at room temperature for 4 h. The reaction was quenched with 5 mL ice cold water and then diluted with EtOAc (300 mL). The phases were separated and the organic phase was washed with sat. NaHCO₃, water and brine. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. Recrystallization was done in CHCl₃/Et₂O to yield of 2-nitro-4-chloro-2'-methoxycarbonyl-diphenylsulfide 10.9 g, (93%).

To a solution of 2-nitro-4-chloro-2'-methoxycarbonyl-diphenylsulfide (10.3 g, 32 mmol) in 78% ethanol (200 mL) a solution of CaCl₂ (2.3 g, 19 mmol) in 4 mL water was added. Zn dust (68.9 g, 1.05 mol) was added and the mixture was refluxed for 3 h. The hot mixture was filtered through a celite pad and washed with hot ethanol. The filtrate was concentrated *in vacuo* to obtain a solid product 2-amino-4-chloro-2'-methoxycarbonyl-diphenylsulfide; yield 10.01 g, (98%).

To a solution of 2-amino-4-chloro-2'-methoxycarbonyl-diphenylsulfide (9.4 g, 32 mmol) in ethanol, 1N KOH (67 mL, 67 mmol) was added and the mixture was refluxed for 2 h. The ethanol was removed and the solution

was cooled to 0°C. The product 2-amino-4-chloro-2'-carboxyl-diphenylsulfide was precipitated by dropwise addition of conc. HCl to pH 3. The precipitate was filtered and collected and dried; yield 8.5 g, (95%).

To a solution of 2-amino-4-chloro-2'-carboxyl-diphenylsulfide (8.4 g, 30 mmol) in dry CH₂Cl₂, 4-dimethylaminopyridine (1.2 g, 9 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10.1 g, 53 mmol) were added and stirred at room temperature overnight. The solution was concentrated *in vacuo*, then diluted with water (200 mL) and ether (50 mL) and placed in refrigerator to precipitate out the final product 8-chloro-10,11-dihydrodibenzo[b,f][1,4]thiazepine-11-one. The precipitate was filtered and dried under vacuum; yield 7.2g, (92%).

To a stirred solution of 8-chloro-11-oxo-dibenzo[b,f][1,4]thiazepine (0.639 g, 2.44 mmol) in dry toluene(20 mL) was added PCl₅ (0.610 g, 2.93 mmol) in one portion and then refluxed for 4 h. The solvent was removed *in vacuo* and the imino chloride was dried under vacuum. To a solution of the imino chloride (0.684 g, 2.44 mmol) in dry acetonitrile (20 mL) was added 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) (2.0 mL, 13.4 mmol) and 1-piperonylpiperazine (1.0 g, 4.54 mmol). The mixture was refluxed overnight, cooled to room temperature and the solvent removed *in vacuo*. The resulting oil was diluted with ether (250 mL). The organic phase was washed with water (3x20 mL), brine (20 mL) and concentrated *in vacuo*. Purification of the product was conducted on silica gel using ethyl acetate:hexane (50:50) as the eluant to give 0.302 g (60%) of the product as colourless solid; m.p. 170-172°C.

The hydrochloride salt was subsequently prepared in the manner described in example 1, and the title compound was obtained as an off-white solid; m.p.190-92°C.

Example 84-chloro-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4] diazepine

To a stirred solution of anisole (0.40 mL, 3.68 mmol) in dry toluene (2.00 mL) was added titanium tetrachloride (0.24 mL, 2.18 mmol) at room temperature under argon. The mixture was then treated with 1-piperonylpiperazine (2.07 g, 9.40 mmol) and 4-chloro-11-oxo-10,11-dihydro-5*H*-dibenzo[b,e][1,4]diazepine (0.49 g, 2.00 mmol) (Giani et al, *supra*) and diluted with toluene (1.00 mL). After more 1-piperonylpiperazine (1.19 g, 5.40 mmol) was added, toluene (8.00 mL) was added and the resulted reaction mixture was heated at reflux for 6 h before it was cooled to 60°C. Isopropanol (0.80 mL), celite (0.40 g) and ammonia (30%, 0.50 mL) were added sequentially and the whole mixture was filtered hot. Upon cooling to room temperature, the filtrate was concentrated *in vacuo* to dryness and the residue was subjected to column chromatography using ethyl acetate/hexanes (1/2) as the eluent. Thus 0.63 g (70%) of the title compound was afforded as a light yellow solid; m.p. 160-162°C; MS 447 ($M^+ + 1$).

In a like manner, there was prepared the following additional compounds:

- a) 7,8-dichloro-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine,
62%, m.p. 92-94°C; MS 480 ($M^+ - 1$) from 7,8-dichloro-11-oxo-10,11-dihydro-5*H*-dibenzo[b,e][1,4]diazepine.

The sulfuric acid salt of the title compound was subsequently prepared by the following procedures: to the solution of base (30 mg, 0.062 mmol) in 0.5 mL of methanol was added sulfuric acid (0.13 mL, 1.0 M, 0.12 mmol) at room temperature. The mixture was stirred for 5 minutes, followed by the addition of diethyl ether (2.0 mL). The generated precipitate was filtered and dried under vacuum to yield 38 mg (90%) of the expected sulfuric acid salt

as a light yellow solid; m.p. $>270^{\circ}\text{C}$ (dec.); MS 579 (M^{+}), 481 ($\text{M}^{+} - \text{H}_2\text{SO}_4$).

b) 2-trifluoromethyl-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine, 92%, m.p. $76-78^{\circ}\text{C}$; MS 481 ($\text{M}^{+} + 1$) from 2-trifluoromethyl-11-oxo-10,11-dihydro-5*H*-dibenzo[b,e][1,4]diazepine.

c) 2,7,8-trichloro-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine, 86%, m.p. $182-185^{\circ}\text{C}$; MS 515 ($\text{M}^{+} + 1$) from 2,7,8-trichloro-11-oxo-10,11-dihydro-5*H*-dibenzo[b,e][1,4]diazepine.

d) 3-chloro-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine 98%, m.p. $70-72^{\circ}\text{C}$; MS 447 ($\text{M}^{+} + 1$) from 3-chloro-11-oxo-10,11-dihydro-5*H*-dibenzo[b,e][1,4]diazepine.

e) 2-methoxy-11-(4-piperonyl-1-piperazinyl)-5*H*-dibenzo[b,e][1,4]diazepine, 14%, m.p. $126-128^{\circ}\text{C}$; MS 443 ($\text{M}^{+} + 1$) from 2-methoxy-11-oxo-10,11-dihydro-5*H*-dibenzo [b,e][1,4]diazepine.

f) 4-nitro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine 55%, m.p. $142-144^{\circ}\text{C}$; MS 459 ($\text{M}^{+} + 1$) from 4-nitro-dibenz[b,f][1,4]oxazepin-11(10*H*)-one (Klunder et al, supra).

g) 4-cyano-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, from 4-cyano-dibenz[b,f][1,4]oxazepin-11(10*H*)-one.

h) 4-chloro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, m.p. $146-148^{\circ}\text{C}$; from 4-chlorodibenz[b,f][1,4]oxazepin-11(10*H*)-one.

Example 9

2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine

To a stirred solution of 2-nitro-10-oxo-dibenzo[b,f]thiepine (0.54 g, 2.00 mmol) and 1-piperonylpiperazine (2.04 g, 9.26 mmol) in toluene (15 mL) was added titanium tetrachloride (0.24 mL, 2.2 mmol) at room temperature under argon. The resulted mixture was heated at reflux for 3.5h and then cooled down to room temperature. The whole mixture was poured into a saturated sodium bicarbonate solution (50 mL). After separation, the aqueous phase was extracted with dichloromethane (2x50 mL). The combined organic solution was dried (MgSO_4), filtered and concentrated *in vacuo* to dryness. The residue was subjected to column chromatography using ethyl acetate/hexanes (1/2) as eluent. Thus 0.161 g (17%) of the title compound was obtained as a yellow solid; m.p. 188-190°C; MS 474 ($\text{M}^+ + 1$).

Example 10

Receptor Binding Assay

D2 and D4 receptor-binding affinities of the compounds of examples 1 to 9 were evaluated according to their ability to reduce binding of ^3H -spiperone as compared to the reference compound clozapine. The potency of the test compound to reduce ^3H -spiperone binding directly correlated to its binding affinity for the receptor.

D4 Receptor Preparation

HEK 298 (human embryonic kidney) cells stably transfected with human D4 receptor (D4.2 sub-type) were grown in NUNC cell factories for 5 days (75% confluency) without a media change and removed with versene (approximately 19mg of cells per cell factory tray). The cells were then centrifuged in a Sorval centrifuge for 10 minutes, 5000rpm (GS3 rotor) and the pellets quickly frozen in liquid nitrogen and stored at -80°C until used in binding assay. When used in the assay, cells were thawed on ice for 20 minutes and then 10 mL of incubation buffer (50 mM Tris, 1 mM EDTA, 4 mM MgCl_2 , 5 mM KCl, 1.5 mM CaCl_2 , 120 mM NaCl, pH7.4) was added. The cells were then vortexed to resuspend pellet and homogenized with a Kinematica CH-6010 Kriens-LU homogenizer for 15 seconds at setting 7.

Concentration of receptor protein was determined using the Pierce BCA assay.

D2 Receptor Preparation

GH₄C₁ (rat pituitary) cells stably transfected with the human D2 receptor (short isoform) were grown in CO₂ independent media in roller bottles (1500cm²) for 10 days. 100µM ZnSO₄ was added to the cells (the D2 promoter being zinc inducible). After 16 hours, fresh media was added to allow the cells to recover for 24 hours. The cells were harvested using versene and then centrifuged in a Sorval centrifuge for 10 minutes, at 5000 rpm (GS3 rotor). Pellets were quickly frozen in liquid nitrogen and stored at 80°C until used in the binding assays. When used in the assay, cells were thawed on ice for 20 minutes. Each roller bottle produced approximately 72mg of protein. 10 mL of incubation buffer was added to the pellets which were then vortexed, resuspended and homogenized with a Kinematica CH-6010 Kriens-LU homogenizer for 15 seconds at setting 7. The receptor protein concentration was determined using the Pierce BCA assay.

Total Spiperone Binding Assay

The incubation was started by the addition of 500µl (50µg protein) membrane homogenate to a solution of 900µl incubation buffer and 100µl (0.25 nM final conc.) ³H-spiperone (90 Ci/mmol Amersham diluted in borosilicate glass vial) in 12 X 75 mm polypropylene tubes. The tubes were vortexed and incubated at room temperature for 90 minutes. The binding reaction was stopped by filtering using a Brandell Cell Harvester. The samples were filtered under vacuum over glass fibre filters (Whatman GF/B) presoaked for 2 hours in 0.3% polyethylenimine (PEI) in 50 mM Tris buffer (pH7.4). The filters were then washed 3 times with 5 mL ice cold 50 mM Tris buffer (pH7.4). Individual filter disks were put in scintillation vials (Biovials, Bechman). Ready Protein Plus liquid scintillant (5 mL, Beckman) was added and the vials counted by liquid scintillation spectrophotometry (Beckman LSC 6500) after equilibrating for three hours at room temperature to determine total binding (B_T).

Non-Specific Binding Assay for D4

The incubation was started by the addition of 500 μ l (50 μ g protein) membrane homogenate to a solution of 400 μ l incubation buffer, 100 μ l 3 H-spiperone (90 Ci/mmol Amersham diluted in borosilicate glass vial to 0.25 nM final conc.) and 500 μ l (30 μ M final conc.) of fresh dopamine (Research Biochemicals Inc., light protected and dissolved in incubation buffer) in 12 X 75 mm polypropylene tubes. The tubes were vortexed and incubated at room temperature for 90 minutes at which time the binding reaction was stopped by filtering. The filters were washed and counted using the same procedure as in the total binding assay described above to give the non-specific binding value (NSB).

Non-Specific Binding Assay for D2

This assay employed the same procedures as the non-specific binding assay for D4 with the exception that 2 μ M (final conc.) of (-) sulpiride (Research Chemicals Inc.) was used in place of dopamine.

Displacement Binding Assay

The incubation was started by the addition to 12 X 75 mm polypropylene tubes 500 μ l (50 μ g protein) membrane homogenate to a solution of 400 μ l incubation buffer, 100 μ l (0.25 final conc.) 3 H-spiperone (90Ci/mmol, Amersham, diluted in borosilicate glass vial to) and 500 μ l of test compound that was prepared from 1 mM stock dissolved in DMSO and stored at -20 $^{\circ}$ C in polypropylene cryogenic storage vials until dilution in incubation buffer in borosilicate glass vials. The tubes were vortexed and incubated at room temperature for 90 minutes at which time the binding reaction was stopped by filtering. The filters were washed and counted using the same procedure as in the total binding assay described above to give the displacement binding value (B_D).

Calculations

The test compounds were initially assayed at 1 and 0.1 μ M and then at a range of concentrations chosen such that the middle dose would cause






about 50% inhibition of ^3H -spiperone binding. Specific binding in the absence of test compound (B_0) was the difference of total binding (B_T) minus non-specific binding (NSB) and similarly specific binding (in the presence of test compound) (B) was the difference of displacement binding (B_D) minus non-specific binding (NSB). IC_{50} was determined from an inhibition response curve, logit-log plot of $\%B/B_0$ vs concentration of test compound.






K_i was calculated by the Cheng and Prustoff transformation:






$$K_i = \text{IC}_{50} / (1 + [L]/K_D)$$





where $[L]$ is the concentration of ^3H -spiperone used in the assay and K_D is the dissociation constant of ^3H -spiperone determined independently under the same binding conditions. Assay results are reported in the following Table:

D4 AFFINITY AND SELECTIVITY

COMPOUND	STRUCTURE	Ki	D2/D4
clozapine		23	10
11-(4-piperonyl)-1-piperazinyl-dibenz[b,f][1,4]oxazepine		30	32.7
8-chloro-11-(4-piperonyl)-1-piperazinyl-dibenz[b,f][1,4]oxazepine		4	23.8
8-methyl-11-(4-piperonyl)-1-piperazinyl-dibenz[b,f][1,4]oxazepine		143	9.8
7,8-dimethyl-11-(4-piperonyl)-1-piperazinyl-5H-dibenzo[b,f][1,4] diazepine		266	14.1

COMPOUND	STRUCTURE	Ki	D2/D4
11-(4-piperonyl)-1-piperazinyl-5H-dibenzo[b,e][1,4]diazepine		63	6
2-Chloro-11-(4-piperonyl)-1-piperazinyl-5H-dibenzo[b,e][1,4]diazepine		76	7.3
8-chloro-11-(4-piperonyl)-1-piperazinyl)dibenzo[b,f][1,4]thiazepine		24	63
4-chloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4] diazepine		34	10.6
7,8-dichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine		61	27.4

COMPOUND	STRUCTURE	Ki	D2/D4
2-trifluoromethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo [b,e][1,4]diazepine		73.5	1.9
2,7,8-trichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine		149	15.7
3-chloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine		23.5	24.9
2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4] diazepine		15	5.1
4-nitro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4] oxazepine		24.5	53.2

COMPOUND	STRUCTURE	Ki	D2/D4
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine		15.3	281
2-chloro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine		8.3	15.9
4-cyano-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine		119	82.1
4-chloro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine		57	99.2

Example 11

Functional Assay

The D4 receptor responds to dopamine and other agonists by reducing adenylyl cyclase mediated production of cyclic AMP. Particular test compounds were assayed for their ability to reverse dopamine inhibition of

adenyl cyclase by the following procedure. Forskolin was used to elevate the basal adenyl cyclase activity.

CHO Pro 5 cells stably expressing human D4 receptors were plated in 6 well plates in DMEM (Dulbecco's Modified Eagle Medium)/F12(Nutrient Mixture F12 (Ham)) media with 10% FCS (fetal calf serum) and G418 (Geneticin Disulfate), and incubated at 37°C in a CO₂ incubator. The cells were allowed to grow to about 70% confluence before use in the assay.

Antagonist Assay

The culture media of each well was removed by aspiration, and the wells were washed once with serum free media (SFM) (DMEM/F12) media. Then 2 mL of fresh SFM+IBMX media (SFM with 0.5 mM IBMX (3-isobutyl-1-methylxanthine 0.1% ascorbic acid and 10µM pargyline) was added to each well and then incubated at 37°C for 10 minutes in CO₂ incubator. Following incubation, SFM+IBMX media was aspirated and fresh SFM+IBMX media was added to wells separately with one of a) forskolin (10µM final conc.); b) dopamine and forskolin (both 10µM final conc.); and c) test compound (1 and 0.1µM), and dopamine and forskolin (both 10µM final conc.). Basal adenyl cyclase activity was determined from wells with only SFM+IBMX media added.

The cells were then incubated at 37°C for 30 minutes in a CO₂ incubator. Following incubation the media was aspirated from each well and then washed once with 2 mL of PBS (phosphate buffered saline). Each well was then treated with 1 mL cold 95% ethanol:5 mM EDTA (2:1) at 4°C for 1 h. The cells from each well were then scraped and transferred into individual Eppendorf tubes. The tubes were centrifuged for 5 minutes at 4°C, and the supernatants were transferred to new Eppendorf tubes. The pellets were discarded and the supernatants dried using a SpeedVac. The extracts were then reconstituted in 600µL of 0.1M sodium acetate buffer, pH 6.1, and stored at 4°C until assayed for cAMP concentration. cAMP content measured in fmoles/well for each extract was determined by EIA (enzyme-

immunoassay) using Amersham Biotrak cAMP EIA kit (Amersham RPN 225).

Total inhibition (I_0) of forskolin-stimulated adenylyl cyclase activity by dopamine was determined as the difference in concentration of cAMP in the forskolin-treated cells (C_f) and dopamine-forskolin treated cells (C_d).

$$I_0 = C_f - C_d$$

Net inhibition (I) of forskolin-stimulated adenylyl cyclase activity by dopamine in the presence of an antagonist was determined as the difference in concentration of cAMP in the forskolin-treated cells (C_f) and test compound, dopamine and forskolin treated cells (C).

The ability of a test compound to reverse the dopamine inhibition (% reversal, %R) was determined by the formula:

$$\%R = (1 - I/I_0) \times 100$$

Antagonist Activity


COMPOUND	% REVERSAL OF DOPAMINE EFFECT	
	1 μ M	10 μ M
clozapine	10	62
11-(4-piperonyl)-1-piperazinyll- dibenz[b,f][1,4]oxazepine	40	50
8-chloro-11-(4-piperonyl)-1-piperazinyll- dibenz[b,f][1,4]oxazepine	46	68
3-chloro-11-(4-piperonyl)-1-piperazinyll- 5H-dibenzo[b,e][1,4]diazepine	19	50
2-chloro-10-(4-piperonyl)-1- piperazinyll)dibenzo[b,f]thiepine	47	40

Agonist Assay

To D4 stably expressing CHO cells prepared as previously described were added test compound and forskolin (10 μ M final concentration). The cells were incubated, extracted and measured for cAMP concentration as above. Agonist activity of a test compound would result in a decrease in cAMP concentration compared to cells treated with forskolin (C_f) only. No decrease was observed for any of the compounds tested, therefore none exhibited dopamine agonist activity. It is predicted based on structural and biological functional similarities that the remaining compounds of the invention would also exhibit dopamine antagonist activity.

WE CLAIM:

1. A compound of Formula I:



wherein:

A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;

X₁ is selected from CH₂, O, NH, S, C=O, CH-OH, CH-N(C₁₋₄alkyl)₂, C=CHCl, C=CHCN, N-C₁₋₄alkyl, N-acetyl, SO₂ and SO;

X₂--- is selected from N=, CH₂-, CH=, C(O)-, O-, and S-;

Y is selected from CH and N;

R₁ represents C₁₋₄alkyl;

n is 0, 1 or 2;

q is 1 or 2;

R₂ is C₁₋₆alkyl optionally incorporating a heteroatom selected from N, O and S;

D is cyclohexane or benzene; and

E is a saturated or unsaturated 5- or 6-membered heterocycle incorporating 1, 2 or 3 heteroatoms selected from O, N, and S, wherein E is optionally substituted with 1 or 2 substituents selected from halogen, C₁₋₄alkyl and halogen-substituted C₁₋₄alkyl;

and acid addition salts, solvates and hydrates thereof.

2. A compound according to claim 1, wherein rings A and B are independently selected from benzene, pyridine, pyrimidine, pyrazine,

pyridazine, pyrrole, imidazole, triazole, pyrazole, thiophene, thiazole, and pyran, optionally substituted with substituents selected independently from hydroxyl, halo, C₁₋₄alkyl, amino, nitro, cyano, halo-substituted C₁₋₄alkyl, C₁₋₄alkoxy, halo-substituted C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄acyl, halo-substituted C₁₋₄acyl, cyclo-C₁₋₇alkylthio-C₁₋₄alkylene, C₁₋₄alkylthio, halo-substituted C₁₋₄alkylthio, cyanothio, tetrazolyl, N-piperidinyl, N-piperazinyl, N-morpholinyl, acetamido, C₁₋₄alkylsulfonyl, halosulfonyl, halo-substituted C₁₋₄alkylsulfonyl, C₁₋₄alkylsulfoxyl, sulfonamido, C₁₋₄alkylseleno, and OSO₃H.

3. A compound according to claim 2, wherein ring A is selected from benzene and pyridine and ring B is selected from benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, triazole, pyrazole, thiophene, thiazole, furan, and pyran wherein either ring is optionally substituted with 1 or 2 substituents selected independently from hydroxyl, halo, C₁₋₄alkyl, amino, nitro, cyano, halo-substituted C₁₋₄alkyl, C₁₋₄alkoxy, halo-substituted C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄acyl, halo-substituted C₁₋₄acyl, cyclo-C₁₋₇alkyl, thio-C₁₋₄alkylene, C₁₋₄alkylthio, halo-substituted C₁₋₄alkylthio, cyanothio, tetrazolyl, N-piperidinyl, N-piperazinyl, N-morpholinyl, acetamido, C₁₋₄alkylsulfonyl, halosulfonyl, halo-substituted C₁₋₄alkylsulfonyl, C₁₋₄alkylsulfoxyl, sulfonamido, C₁₋₄alkylseleno, and OSO₃H.
4. A compound according to claim 3, wherein rings A and B are both benzene optionally substituted with 1 or 2 substituents selected independently from hydroxyl, halo, C₁₋₄alkyl, amino, nitro, cyano, halo-substituted C₁₋₄alkyl, C₁₋₄alkoxy, halo-substituted C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄acyl, halo-substituted C₁₋₄acyl, cyclo-C₁₋₇alkyl, thio-C₁₋₄alkylene, C₁₋₄alkylthio, halo-substituted C₁₋₄alkylthio, cyanothio, tetrazolyl, N-piperidinyl, N-piperazinyl, N-morpholinyl, acetamido, C₁₋₄alkylsulfonyl, halosulfonyl, halo-substituted C₁₋₄alkylsulfonyl, C₁₋₄alkylsulfoxyl, sulfonamido, C₁₋₄alkylseleno, and

OSO₃H.

5. A compound according to claim 1, wherein ring A is benzene substituted by 1 or 2 substituents selected from chloro, methyl, methylthio, nitro and cyano.
6. A compound according to claim 1, wherein ring B is benzene substituted by 1 or 2 substituents selected from fluoro, chloro, trifluoromethyl, methoxy, nitro and cyano.
7. A compound according to claim 1, wherein X₁ is selected from O, NH and S.
8. A compound according to claim 1, wherein X₂--- is selected from N=, and CH=.
9. A compound according to claim 1, wherein X₁ and X₂--- with rings A and B form a tricycle selected from 5*H*-dibenzo[b,e][1,4]diazepine that is substituted by one of 7,8-dichloro, 7,8-dimethyl, 2-chloro, 3-chloro, 4-chloro, 2,4-chloro, 4,7,8-trichloro, 2-trifluoromethyl 1-fluoro, or 2-methoxy; dibenz[b,f][1,4]oxazepine that is substituted by one of 4-nitro, 8-chloro, 4-cyano or 4-chloro; dibenzo[b,f]thiepine that is substituted by one of 2-nitro or 2-chloro; 11*H*-dibenzo[b,f]thiepin that is substituted by 2-methylthio; and dibenzo[b,f][1,4]thiazepine that is substituted by 8-chloro.
10. A compound according to claim 9, wherein ring D is benzene.
11. A compound according to claim 9, wherein R₂ is -CH₂-.
12. A compound according to claim 9, wherein ring E is a 5-membered heterocycle containing two heteroatoms.

13. A compound according to claim 12, wherein ring E contains two oxygen atoms.
14. A compound according to claim 9, wherein ring E is a six-membered heterocycle containing two heteroatoms.
15. A compound according to claim 14, wherein ring E contains two oxygen atoms.
16. A compound according to claim 12, wherein ring D is benzene.
17. A compound according to claim 16, wherein R_2 is $-CH_2-$.
18. A compound according to claim 9, wherein R_2 together with rings D and E form a piperonyl group.
19. A compound according to claim 1, which is selected from:
 - 11-(4-piperonyl)-1-piperaziny]-dibenz[b,f][1,4]oxazepine;
 - 8-chloro-11-(4-piperonyl)-1-piperaziny]-dibenz[b,f][1,4]oxazepine;
 - 8-methyl-11-(4-piperonyl)-1-piperaziny]-dibenz[b,f][1,4]oxazepine;
 - 7,8-dimethyl-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 2-chloro-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 8-chloro-11-(4-piperonyl)-1-piperaziny]-dibenzo[b,f][1,4]thiazepine;
 - 4-chloro-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 7,8-dichloro-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 2-trifluoromethyl-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 2,7,8-trichloro-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;
 - 3-chloro-11-(4-piperonyl)-1-piperaziny]-5H-dibenzo[b,e][1,4]diazepine;

2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
4-cyano-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;
4-chloro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;
4-nitro-11-(4-piperonyl-1-piperazinyl)-dibenz[b,f][1,4]oxazepine; and
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.

20. A compound according to claim 19, which is selected from:

11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-methyl-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
7,8-dimethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
8-chloro-11-(4-piperonyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine;
2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
7,8-dichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
2-trifluoromethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
2,7,8-trichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; and
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.

21. A compound according to claim 19, which is selected from:

11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-methyl-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
7,8-dimethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
8-chloro-11-(4-piperonyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine; and

2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.

22. A compound according to claim 19, which is selected from:
11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
7,8-dimethyl-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
8-chloro-11-(4-piperonyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine;
4-chloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
7,8-dichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
2,7,8-trichloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
3-chloro-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;
4-nitro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
4-cyano-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;
4-chloro-11-(4-piperonyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine;
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine; and
2-chloro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.
23. A compound according to claim 19, which is selected from:
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine;
2-methoxy-11-(4-piperonyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; and
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine.
24. A compound according to claim 19, which is selected from:
2-nitro-10-(4-piperonyl-1-piperazinyl)dibenzo[b,f]thiepine; and
8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4]oxazepine.
25. The compound 8-chloro-11-(4-piperonyl)-1-piperazinyl)-dibenz[b,f][1,4] oxazepine.

26. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1, and a pharmaceutically acceptable carrier.
27. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 19, and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 94/00687

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D413/12 C07D405/12 C07D417/12 C07D409/12 A61K31/645

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 189 310 (SPOFA) 30 July 1986 see the whole document ---	1-27
A	CHEMICAL ABSTRACTS, vol. 90, no. 15, 9 April 1979, Columbus, Ohio, US; abstract no. 121655j, page 653 ; see abstract & CS,A,174 564 (M. PROTIVA ET AL.) --- -/--	1-27



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

29 March 1995

Date of mailing of the international search report

3. 04. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

Int: International Application No

PCT/CA 94/00687

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>COLLECTION OF CZECHOSLOWAK CHEMICAL COMMUNICATIONS, vol.40, no.11, 1975, PRAGUE CZ pages 3386 - 3398 J.O. JILEK ET AL. 'Potential neuroleptics; N-aralkyl, N-(aroylalkyl) and N-pyridyl derivatives of 10-piperazino-10,11-dihydro dibenzo[b,f]thiepins' see the whole document, particularly page 3387, compound V</p> <p>-----</p>	1-27

INTERNATIONAL SEARCH REPORT

International application no.

PCT/CA94/00687

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
For economical reasons (see PCT-Search Guidelines, C-III 2.1) the search has been limited to the classification units governed by the compounds of the examples or of those listed in claims 19-25.
Claims searched incompletely: 1-12, 14-17, 26, 27
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 94/00687

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0189310	30-07-86	CA-A- 1238047	14-06-88
		JP-A- 61204181	10-09-86
		US-A- 4678788	07-07-87

CS-A-174564		NONE	
